In the EXPERT‐C trial, digital droplet PCR (ddPCR) was used to investigate mutations in specific genes such as KRAS/BRAF in ctDNA from baseline blood samples of patients with rectal cancer who were treated with capecitabine with OX followed by nCRT, surgery and capecitabine with OX ± cetuximab as aCT.94 In conclusion, the detection of a KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. The gene discussed is BRAF; the disease is rectal cancer.